FDA Approves Midazolam Nasal Spray for Seizure Clusters
The US Food and Drug Administration (FDA) has approved midazolam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in epilepsy patients aged 12 or above.Midazolam nasal spray is the first and only FDA-approved nasal option for treating seizure clusters. It is packaged as a single-use treatment that can be carried with a patie
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies